<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021406</url>
  </required_header>
  <id_info>
    <org_study_id>2017-P2-104-04</org_study_id>
    <nct_id>NCT05021406</nct_id>
  </id_info>
  <brief_title>Extension Study of Carvedilol RCT Study</brief_title>
  <official_title>Extension Study of Carvedilol for the Prevention of the Esophageal Varices Progression on HBV Cirrhotic Patients With Anti-Viral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another&#xD;
      2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the&#xD;
      prevention of esophageal varices in treated HBV cirrhotic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carvedilol has been shown to be more potent in decreasing portal hypertension than&#xD;
      propranolol. But the efficacy of carvedilol to prevent esophageal varices progression in&#xD;
      nucleoside analogue (NUCs) treatment HBV related cirrhotic patients was unclear. Previous RCT&#xD;
      study aimed to explore the effects of carvedilol for the prevention of the esophageal varices&#xD;
      progression on HBV cirrhotic patients with anti-viral therapy has been conducted&#xD;
      (NCT03736265). Patients who have completed 2-years treatment in RCT Study of carvedilol will&#xD;
      receive another 2-years extension therapy, aiming to investigate the long-term efficacy of&#xD;
      carvedilol for the prevention of esophageal varices in treated HBV cirrhotic patients.&#xD;
      Patients were allocated according to the outcome of EDGs at 2-year during RCT study. Patients&#xD;
      will be assessed at baseline and every six months for blood cell count, liver function test,&#xD;
      HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan. A third EGDs will be&#xD;
      performed at 4-year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progression incidence of esophageal varices after 4-year therapy</measure>
    <time_frame>4-year</time_frame>
    <description>Progression of esophageal varices defines as follows:&#xD;
Varices developed from small (F1) to medium or large (F2/F3)&#xD;
Varices developed from medium (F2) to large (F3)&#xD;
New-onset red sign without change in the degree of varices.&#xD;
Bleeding from esophageal varices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of liver cirrhosis decompensation</measure>
    <time_frame>4-year</time_frame>
    <description>Cumulative rate of liver cirrhosis decompensation, including bleeding, ascites, hepatic encephalopathy, ect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hepatic cellular carcinoma, death or liver transplantation.</measure>
    <time_frame>4-year</time_frame>
    <description>Cumulative rate of hepatic cellular carcinoma, death or liver transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of non-invasive assessment score reflecting liver fibrosis.</measure>
    <time_frame>4-year</time_frame>
    <description>Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of non-invasive assessment score reflecting liver function.</measure>
    <time_frame>4-year</time_frame>
    <description>Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dynamic change of liver stiffness quantified by transient elastography.</measure>
    <time_frame>4-year</time_frame>
    <description>The dynamic change of liver stiffness quantified by transient elastography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Carvedilol+ NUCs therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to Carvedilol combined with NUCs group during the previous 2-year treatment of RCT study; Patients showed the progression of esophageal varices in NUCs group during the 2-year treatment of RCT study. Based on nucleoside analogue (NUCs), carvedilol will be added to the patients. Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NUCs therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continuing take single or combined nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol 12.5 MG</intervention_name>
    <description>Carvedilol is started at a dose of 6.25 mg once per day, and will increase to a dose of 12.5 mg once per day after 1 week. Target dose will be maintained at 12.5 mg once per day if patients with systolic blood pressure not lower than 90 mm Hg and HR no less than 50 beats/min.</description>
    <arm_group_label>Carvedilol+ NUCs therapy</arm_group_label>
    <other_name>Nucleos(t)ide Analogues</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who completed the 2-year RCT study of carvedilol in HBV cirrhotic patients&#xD;
             with anti-viral therapy;&#xD;
&#xD;
          -  Subjects who are willing to participate the extension study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who refused to receive 2-year EGD examination during the previous RCT study;&#xD;
&#xD;
          -  Subjects who could not compliance with the protocol judged by investigators;&#xD;
&#xD;
          -  Subjects who are not suitable for the study judged by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojuan Ou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojuan Ou, Dr</last_name>
    <phone>+86-010-63138665</phone>
    <email>ouxj16@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoning Wu, Dr</last_name>
    <phone>+86-010-63138665</phone>
    <email>wuxiaoningbs@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Ditan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Xie</last_name>
    </contact>
    <contact_backup>
      <email>Xiewen6218@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyuan Xu</last_name>
    </contact>
    <contact_backup>
      <email>xiaoyuanxu6@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Feng</last_name>
      <email>xyfyfb_1@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bingqiong Wang</last_name>
      <phone>+86-13031136358</phone>
      <email>13031136358@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minghui Li</last_name>
      <email>wuhm2000@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li</last_name>
      <email>13699119545@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Yanbian University</name>
      <address>
        <city>Yanji</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxin Piao</last_name>
      <email>15526770394@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Jiang</last_name>
    </contact>
    <contact_backup>
      <email>jiang.wei@zs-hospital.sh.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingyi Xu</last_name>
    </contact>
    <contact_backup>
      <email>xumingyi@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jilin Cheng</last_name>
      <email>chengjilin@shphc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
      <email>tjlplxg@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital, Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Han</last_name>
      <email>hantaomd@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Xiqing Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai Li</last_name>
      <email>15202265600@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital</name>
      <address>
        <city>Xinjiang</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Wang</last_name>
      <email>wxz125@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojuan Ou</investigator_full_name>
    <investigator_title>Beijing Friendship Hospital</investigator_title>
  </responsible_party>
  <keyword>Portal Hypertension</keyword>
  <keyword>Esophageal Varices</keyword>
  <keyword>Carvedilol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

